M. Ploeg, K. Aben, and L. Kiemeney, The present and future burden of urinary bladder cancer in the world, World Journal of Urology, vol.102, issue.2, pp.289-93, 2009.
DOI : 10.1007/s00345-009-0383-3

R. Sylvester, A. Van-der-meijden, W. Oosterlinck, J. Witjes, C. Bouffioux et al., Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-471, 2006.
DOI : 10.1016/j.eururo.2005.12.031

J. Stein, G. Lieskovsky, R. Cote, S. Groshen, A. Feng et al., Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients, Journal of Clinical Oncology, vol.19, issue.3, pp.666-75, 2001.
DOI : 10.1200/JCO.2001.19.3.666

S. Shariat, P. Karakiewicz, G. Palapattu, Y. Lotan, C. Rogers et al., Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium, The Journal of Urology, vol.176, issue.6, pp.2414-2436, 2006.
DOI : 10.1016/j.juro.2006.08.004

G. Sonpavde, C. Sternberg, J. Rosenberg, N. Hahn, M. Galsky et al., Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium, The Lancet Oncology, vol.11, issue.9, pp.861-70, 2010.
DOI : 10.1016/S1470-2045(10)70086-3

M. Pollak, The insulin and insulin-like growth factor receptor family in neoplasia: an update, Nature Reviews Cancer, vol.20, issue.3, pp.159-69, 2012.
DOI : 10.1200/JCO.2002.06.140

D. Sachdev and Y. D. , Disrupting insulin-like growth factor signaling as a potential cancer therapy, Molecular Cancer Therapeutics, vol.6, issue.1, pp.1-12, 2007.
DOI : 10.1158/1535-7163.MCT-06-0080

N. Gonzalez-roibon, J. Kim, S. Faraj, A. Chaux, S. Bezerra et al., Insulin-like Growth Factor-1 Receptor Overexpression Is Associated With Outcome in Invasive Urothelial Carcinoma of Urinary Bladder: A Retrospective Study of Patients Treated Using Radical Cystectomy, Urology, vol.83, issue.6, pp.1444-1441, 2014.
DOI : 10.1016/j.urology.2014.01.028

M. Rochester, N. Patel, B. Turney, D. Davies, I. Roberts et al., The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer, BJU International, vol.62, issue.6, pp.1396-401, 2007.
DOI : 10.1021/mp060001j

D. Metalli, F. Lovat, F. Tripodi, M. Genua, S. X. Spinelli et al., The Insulin-Like Growth Factor Receptor I Promotes Motility and Invasion of Bladder Cancer Cells through Akt- and Mitogen-Activated Protein Kinase-Dependent Activation of Paxillin, The American Journal of Pathology, vol.176, issue.6
DOI : 10.2353/ajpath.2010.090904

M. Genua, S. X. Buraschi, S. Peiper, S. Gomella, L. Belfiore et al., Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells, PLoS ONE, vol.285, issue.6, p.40148, 2012.
DOI : 10.1371/journal.pone.0040148.s002

J. Watson, K. Burling, P. Fitzpatrick, E. Kay, J. Kelly et al., Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder, BJU International, vol.52, issue.5, pp.694-701, 2009.
DOI : 10.1172/JCI200421358

A. Lee and Y. D. , Targeting IGF-1R: at a crossroad, Oncology, vol.25, issue.6, pp.535-541, 2011.

N. Stransky, C. Vallot, F. Reyal, I. Bernard-pierrot, S. De-medina et al., Regional copy number???independent deregulation of transcription in cancer, Nature Genetics, vol.12, issue.12, pp.1386-96, 2006.
DOI : 10.1152/physiolgenomics.00116.2002

B. Bolstad, R. Irizarry, M. Astrand, and T. Speed, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, vol.19, issue.2, pp.185-93, 2003.
DOI : 10.1093/bioinformatics/19.2.185

M. Dai, P. Wang, A. Boyd, G. Kostov, B. Athey et al., Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Research, vol.33, issue.20, p.175, 2005.
DOI : 10.1093/nar/gni179

J. Calderaro, S. Rebouissou, L. De-koning, A. Masmoudi, A. Herault et al., PI3K/AKT pathway activation in bladder carcinogenesis, International Journal of Cancer, vol.27, issue.8, pp.1776-84, 2014.
DOI : 10.1038/onc.2008.241

URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.28518/pdf

C. Garcia-echeverria, M. Pearson, A. Marti, T. Meyer, J. Mestan et al., In vivo antitumor activity of NVP-AEW541???A novel, potent, and selective inhibitor of the IGF-IR kinase, Cancer Cell, vol.5, issue.3, pp.231-240, 2004.
DOI : 10.1016/S1535-6108(04)00051-0

J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. Margolin et al., The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, vol.53, issue.7391, pp.603-610, 2012.
DOI : 10.1002/pbc.20697

M. Kerr, Linear Models for Microarray Data Analysis: Hidden Similarities and Differences, Journal of Computational Biology, vol.10, issue.6, pp.891-901, 2003.
DOI : 10.1089/106652703322756131

URL : http://biostats.bepress.com/cgi/viewcontent.cgi?article=1013&context=uwbiostat

D. Lindgren, A. Frigyesi, S. Gudjonsson, G. Sjodahl, C. Hallden et al., Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome, Cancer Research, vol.70, issue.9, pp.3463-72, 2010.
DOI : 10.1158/0008-5472.CAN-09-4213

M. Uhlen, L. Fagerberg, B. Hallstrom, C. Lindskog, P. Oksvold et al., Tissue-based map of the human proteome, Science, vol.42, issue.D1, p.1260419, 2015.
DOI : 10.1093/nar/gkt1140

A. Biton, I. Bernard-pierrot, Y. Lou, C. Krucker, E. Chapeaublanc et al., Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes, Cell Reports, vol.9, issue.4, pp.1235-1280, 2014.
DOI : 10.1016/j.celrep.2014.10.035

M. Castillo-martin, J. Domingo-domenech, O. Karni-schmidt, T. Matos, and C. Cordon-cardo, Molecular pathways of urothelial development and bladder tumorigenesis, Urologic Oncology: Seminars and Original Investigations, vol.28, issue.4, pp.401-409, 2010.
DOI : 10.1016/j.urolonc.2009.04.019

A. Pavlicek, M. Lira, N. Lee, K. Ching, J. Ye et al., Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871), Molecular Cancer Therapeutics, vol.12, issue.12, pp.2929-2968, 2013.
DOI : 10.1158/1535-7163.MCT-13-0442-T

G. Gullu, S. Karabulut, and M. Akkiprik, Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers, Chinese Journal of Cancer, vol.31, issue.6, pp.266-80, 2012.
DOI : 10.5732/cjc.011.10405

R. Baxter, IGF binding proteins in cancer: mechanistic and clinical insights, Nature Reviews Cancer, vol.52, issue.5, pp.329-370, 2014.
DOI : 10.1007/s10549-008-0046-x

M. Schneider, E. Wolf, A. Hoeflich, and H. Lahm, IGF-binding protein-5: flexible player in the IGF system and effector on its own, Journal of Endocrinology, vol.172, issue.3, pp.423-463, 2002.
DOI : 10.1677/joe.0.1720423

P. Liang, Y. Wang, T. W. , W. W. Liao, A. Shen et al., IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder, Journal of Clinical Pathology, vol.14, issue.7, pp.573-82, 2013.
DOI : 10.1158/1078-0432.CCR-08-0408

F. Atzori, J. Tabernero, A. Cervantes, L. Prudkin, J. Andreu et al., A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.17, issue.19, pp.6304-6316, 2011.
DOI : 10.1158/1078-0432.CCR-10-3336

C. Langer, S. Novello, K. Park, M. Krzakowski, D. Karp et al., Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.32, issue.19, pp.2059-66, 2014.
DOI : 10.1200/JCO.2013.54.4932

I. Mccaffery, Y. Tudor, H. Deng, R. Tang, S. Suzuki et al., Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor, Clinical Cancer Research, vol.19, issue.15, pp.4282-4291, 2013.
DOI : 10.1158/1078-0432.CCR-12-1840

U. Gabriel, C. Bolenz, and M. Michel, Experimental models for therapeutic studies of transitional cell carcinoma, Anticancer Res, vol.27, issue.5A, pp.3163-71, 2007.